Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philipp Holzer

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
ACS Medicinal Chemistry Letters|March 25, 2017
Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking ApproachHenrik Möbitz, Rainer Machauer, Philipp Holzer, et al.
Journal of Medicinal Chemistry|April 12, 2021
Synthesis of the Potent, Selective, and Efficacious β-Secretase (BACE1) Inhibitor NB-360Heinrich Rueeger, Rainer Lueoend, Rainer Machauer, et al.
Chemmedchem|May 9, 2019
Structural States of Hdm2 and HdmX: X-ray Elucidation of Adaptations and Binding Interactions for Different Chemical Compound ClassesJoerg Kallen, Aude Izaac, Suzanne Chau, et al.
Journal of Medicinal Chemistry|July 17, 2015
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt TumorsPhilipp Holzer, Keiichi Masuya, Pascal Furet, et al.
ACS Medicinal Chemistry Letters|August 27, 2016
Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation ApproachChao Chen, Hugh Zhu, Frédéric Stauffer, et al.
Bioorganic & Medicinal Chemistry Letters|March 17, 2010
Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitorsCarole Pissot-Soldermann, Marc Gerspacher, Pascal Furet, et al.
ACS Medicinal Chemistry Letters|July 19, 2023
Discovery of New Binders for DCAF1, an Emerging Ligase Target in the Targeted Protein Degradation FieldAnna Vulpetti, Philipp Holzer, Niko Schmiedeberg, et al.
Bioorganic & Medicinal Chemistry Letters|February 9, 2010
2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitorsMarc Gerspacher, Pascal Furet, Carole Pissot-Soldermann, et al.
Elife|May 13, 2015
A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097Sébastien Jeay, Swann Gaulis, Stéphane Ferretti, et al.
Cancer Research|August 24, 2018
Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201Sébastien Jeay, Stéphane Ferretti, Philipp Holzer, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
ACS Medicinal Chemistry Letters|March 25, 2017
Discovery of Potent, Selective, and Structurally Novel Dot1L Inhibitors by a Fragment Linking ApproachHenrik Möbitz, Rainer Machauer, Philipp Holzer, et al.
Journal of Medicinal Chemistry|April 12, 2021
Synthesis of the Potent, Selective, and Efficacious β-Secretase (BACE1) Inhibitor NB-360Heinrich Rueeger, Rainer Lueoend, Rainer Machauer, et al.
Chemmedchem|May 9, 2019
Structural States of Hdm2 and HdmX: X-ray Elucidation of Adaptations and Binding Interactions for Different Chemical Compound ClassesJoerg Kallen, Aude Izaac, Suzanne Chau, et al.
Journal of Medicinal Chemistry|July 17, 2015
Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt TumorsPhilipp Holzer, Keiichi Masuya, Pascal Furet, et al.
ACS Medicinal Chemistry Letters|August 27, 2016
Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation ApproachChao Chen, Hugh Zhu, Frédéric Stauffer, et al.
Bioorganic & Medicinal Chemistry Letters|March 17, 2010
Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitorsCarole Pissot-Soldermann, Marc Gerspacher, Pascal Furet, et al.
ACS Medicinal Chemistry Letters|July 19, 2023
Discovery of New Binders for DCAF1, an Emerging Ligase Target in the Targeted Protein Degradation FieldAnna Vulpetti, Philipp Holzer, Niko Schmiedeberg, et al.
Bioorganic & Medicinal Chemistry Letters|February 9, 2010
2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitorsMarc Gerspacher, Pascal Furet, Carole Pissot-Soldermann, et al.
Elife|May 13, 2015
A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097Sébastien Jeay, Swann Gaulis, Stéphane Ferretti, et al.
Cancer Research|August 24, 2018
Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201Sébastien Jeay, Stéphane Ferretti, Philipp Holzer, et al.
Pageof 3